X
DNTH icon

Xponance’s Dianthus Therapeutics DNTH Stock Holding History

Xponance’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$451K Buy
4,630
+1,299
+39% +$113K ﹤0.01% 1151
2026
Q1 		$280K Buy
+3,331
New +$193K ﹤0.01% 1305

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Xponance's DNTH Position: Q2 2026 in Review

Xponance increased its Dianthus Therapeutics (DNTH) stake by 39% in Q2 2026, buying an estimated $113K and bringing the position to 4,630 shares worth $451K. The position accounts for ﹤0.01% of the portfolio, ranked #1151.

Xponance first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Xponance held 4,630 shares of Dianthus Therapeutics worth $451K as of Q2 2026.
  • Xponance bought 1,299 Dianthus Therapeutics shares in Q2 2026, an estimated $113K.
  • Dianthus Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1151 holding.
  • Xponance first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.